Literature DB >> 26464714

Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.

Xing-Zhen Sun1, Shu-Yan Li2, Xiang-Yang Tian3, Qing-Quan Wu4.   

Abstract

OBJECTIVE: To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil.
METHODS: The rat model of pulmonary hypertension was established by exposing rats to normobaric intermitent hypoxia [(10 ± 0.5)% O2]. Twenty-four Spraque-Dawley male rats were randomly divided into control group, hypoxic model group and hypoxia with fasudil groups (n=8 each). The mean pulmonary arterial pressure (mPAP), and right ventricle hypertrophy index (RVHI) were measured. Ultrastructure of the right ventricular myocardial cells was observed under transmission electron microscope (TEM). -
RESULTS: The level of mPAP (31.38 ± 1.98) mmHg and RVHI (0.47 ± 0.03) were significantly higher in the hypoxic model group than (15.25 ± 0.91) mmHg and (0.25 ± 0.02) in control group respectively (P<0.01). Transmission electron microscope (TEM) revealed the model group right ventricular mitochondria increased significantly, swelling, cristae blurred, lost, heart muscle Siming dark band was not clear. The level of mPAP (16.63 ± 1.53) mmHg and RVHI (0.27 ± 0.02) were significantly lower in fasudil treatment group than in model group respectively (P<0.01). After the intervention of fasudil right ventricular myocardial injury was significantly reduced.
CONCLUSIONS: Fasudil may partly prevent and reverse the development of pulmonary hypertension and right ventricular hypertrophy and myocardial cell injury.

Entities:  

Keywords:  Fasudil; pulmonary hypertension; rat; right ventricular hypertrophy

Mesh:

Substances:

Year:  2015        PMID: 26464714      PMCID: PMC4583946     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 2.  Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.

Authors:  Ronggui Guan; Xiaoyu Xu; Meihui Chen; Haiyan Hu; Hu Ge; Shijun Wen; Shiyou Zhou; Rongbiao Pi
Journal:  Eur J Med Chem       Date:  2013-10-25       Impact factor: 6.514

Review 3.  [Role of the Rho-kinase pathway in pulmonary arterial hypertension].

Authors:  Yoshihiro Fukumoto
Journal:  Nihon Yakurigaku Zasshi       Date:  2014-04

4.  Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension.

Authors:  Aiping Liu; David Schreier; Lian Tian; Jens C Eickhoff; Zhijie Wang; Timothy A Hacker; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-06-06       Impact factor: 4.733

5.  Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury.

Authors:  Qing Mei Wang; Timothy J Stalker; Yulan Gong; Yoshiyuki Rikitake; Rosario Scalia; James K Liao
Journal:  Vasc Med       Date:  2012-09-26       Impact factor: 3.239

6.  Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.

Authors:  Md Elias-Al-Mamun; Kimio Satoh; Shin-Ichi Tanaka; Toru Shimizu; Suvd Nergui; Satoshi Miyata; Yoshihiro Fukumoto; Hiroaki Shimokawa
Journal:  Circ J       Date:  2014-02-18       Impact factor: 2.993

7.  Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-κB activation in hypoxic pulmonary hypertensive rats.

Authors:  Yan Zhang; Li Dai; Shangjie Wu; Ping Chen; Shuiping Zhao
Journal:  Chin Med J (Engl)       Date:  2014       Impact factor: 2.628

8.  Hypoxic pulmonary vasoconstriction in the absence of pretone: essential role for intracellular Ca2+ release.

Authors:  Michelle J Connolly; Jesus Prieto-Lloret; Silke Becker; Jeremy P T Ward; Philip I Aaronson
Journal:  J Physiol       Date:  2013-06-17       Impact factor: 5.182

Review 9.  Role of Rho-kinase and its inhibitors in pulmonary hypertension.

Authors:  Sy Duong-Quy; Yihua Bei; Zhongmin Liu; Anh Tuan Dinh-Xuan
Journal:  Pharmacol Ther       Date:  2012-12-20       Impact factor: 12.310

10.  Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice.

Authors:  Toru Shimizu; Yoshihiro Fukumoto; Shin-Ichi Tanaka; Kimio Satoh; Shohei Ikeda; Hiroaki Shimokawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-17       Impact factor: 8.311

View more
  1 in total

Review 1.  Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Abdirashit Maripov; Djuro Kosanovic; Norbert Weissmann; Hossein Ardeschir Ghofrani; Akpay Sh Sarybaev; Ralph Theo Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.